Why is the GAAP EPS growth so much higher than the non-GAAP growth, and which number should investors focus on?

Full-year GAAP diluted EPS rose 40% to $11.18 versus 12% growth to $16.47 on a non-GAAP basis. The gap is largely explained by lower share-based compensation acceleration charges (tied to the Reata acquisition in 2023), lower restructuring charges, and an $88.6 million gain on sale of a priority review voucher in 2024. Non-GAAP figures exclude acquisition amortization, impairments, restructuring, and equity investment gains or losses. Management uses non-GAAP EPS for incentive compensation and its 2025 guidance, so investors typically anchor on that measure, while also reviewing GAAP results for one-time items.

Why is 2025 guidance lower than 2024 results?

The 2025 non-GAAP EPS range of $15.25 to $16.25 is below 2024's $16.47, mainly because total revenue is expected to decline by a mid-single-digit percentage at constant currency. Multiple sclerosis product sales, which are the company's largest franchise, are expected to keep falling, and launch growth from LEQEMBI, SKYCLARYS, and ZURZUVAE is only expected to partially offset that decline. Guidance also includes about a $0.35 foreign exchange headwind. Management expects operating margin to be roughly flat, so lower revenue is the main driver of the EPS decline.

How is Biogen's cost base changing, and how much of the savings are already in the numbers?

The Fit for Growth program is expected to deliver about $1 billion in gross savings and $800 million net of reinvestment by the end of 2025. About $400 million of net savings have been achieved since the program started in 2023, and management expects to realize the remainder by year-end 2025. Non-GAAP R&D fell 15% and non-GAAP SG&A fell 3% in 2024. Combined R&D and SG&A for 2025 is guided to about $3.9 billion, so further savings will need to be realized to hold that level.

How significant is LEQEMBI's commercial progress and what are the next catalysts?

LEQEMBI generated approximately $87 million in global in-market sales in Q4 2024, including about $50 million in the U.S., and management described this as continued sequential growth. Biogen's reported Alzheimer's collaboration revenue was $60 million for the full year, reflecting its 50% share of net revenue and royalties. The FDA approved intravenous maintenance dosing, and the subcutaneous maintenance dosing BLA has a PDUFA date of August 31, 2025. Management believes the long-term opportunity remains significant, but the drug is still early in its launch.

How strong is Biogen's balance sheet and cash flow position?

Biogen generated $2.9 billion of operating cash flow and $2.7 billion of free cash flow in 2024. Year-end cash was about $2.4 billion against total debt of about $6.3 billion, for net debt of about $3.9 billion. Current portion of debt rose to $1.75 billion, which investors should monitor for refinancing needs. Diluted share count was steady at about 146 million, and the company did not disclose share repurchases in this filing. Guidance does not include future acquisitions or business development, so any large deal could change the capital allocation picture.

BIIB 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 12, 2025. Cited figures are marked; the original filing is the authoritative source.

Biogen's 8-K (furnished under Item 2.02) reports fourth quarter and full year 2024 results and provides 2025 guidance.

Full-year 2024 total revenue was $9.7 billion^a, down 2% year over year, while GAAP diluted EPS rose 40% to $11.18 (helped by an $88.6 million gain on sale of a priority review voucher and lower operating charges) and non-GAAP diluted EPS rose 12% to $16.47. Fourth-quarter revenue of $2.5 billion grew 3%, with non-GAAP EPS of $3.44 up 17%. Multiple sclerosis product revenue continued to decline (down 7% for the year and 8% in Q4), offset in part by growth in rare disease (up 10%, led by SKYCLARYS and SPINRAZA) and early launches such as LEQEMBI and ZURZUVAE.

The key forward-looking item is 2025 guidance: non-GAAP diluted EPS of $15.25 to $16.25^b, which implies a decline from 2024's $16.47, and total revenue expected to fall by a mid-single-digit percentage at constant currency. Management expects further MS erosion to be only partially offset by launches. Cost discipline is a central theme: the Fit for Growth program is targeted at roughly $800 million in net savings by the end of 2025, with about $400 million already achieved, and combined non-GAAP R&D and SG&A are guided to about $3.9 billion.

Management also expects operating margin to be roughly flat. Balance sheet and cash generation remain solid, with full-year free cash flow of about $2.7 billion^c, year-end cash of about $2.4 billion, total debt of about $6.3 billion, and net debt of about $3.9 billion.

Pipeline news included pruning of four early-stage programs, a Royalty Pharma funding deal of up to $250 million^d for litifilimab, and regulatory milestones for LEQEMBI subcutaneous maintenance (PDUFA August 31, 2025) and SPINRAZA higher dosing (PDUFA September 22, 2025). Guidance excludes any future acquisitions, business development, litigation, or tax and healthcare reform effects.

02—Key points

Key Highlights

FY2024 total revenue of $9.68 billion declined 2% YoY, while Q4 2024 revenue of $2.45 billion grew 3% YoY (2% at constant currency).
FY2024 GAAP diluted EPS rose 40% to $11.18 and non-GAAP diluted EPS rose 12% to $16.47; GAAP results benefited from an $88.6 million gain on sale of a priority review voucher and lower operating charges.
Multiple sclerosis revenue fell 7% to $4.35 billion for FY2024, while rare disease revenue grew 10% to $1.99 billion, led by SKYCLARYS (about $383 million for the year) and SPINRAZA.
2025 guidance calls for non-GAAP diluted EPS of $15.25 to $16.25, below 2024's $16.47, and total revenue down a mid-single-digit percentage at constant currency, including a roughly $0.35 FX headwind.
The Fit for Growth program targets about $800 million in net savings by end-2025, with roughly $400 million achieved to date; combined 2025 non-GAAP R&D and SG&A are guided to about $3.9 billion.
FY2024 free cash flow was about $2.7 billion; year-end net debt was about $3.9 billion (cash of $2.4 billion against $6.3 billion of total debt).
Pipeline actions include discontinuing four early-stage programs (BIIB113, BIIB094, BIIB101, BIIB143) and a Royalty Pharma deal providing up to $250 million in R&D funding for litifilimab, with upcoming FDA PDUFA dates for LEQEMBI subcutaneous maintenance (August 31, 2025) and SPINRAZA higher dose (September 22, 2025).

03—Questions

Frequently Asked Questions

Why is the GAAP EPS growth so much higher than the non-GAAP growth, and which number should investors focus on?
Full-year GAAP diluted EPS rose 40% to $11.18 versus 12% growth to $16.47 on a non-GAAP basis. The gap is largely explained by lower share-based compensation acceleration charges (tied to the Reata acquisition in 2023), lower restructuring charges, and an $88.6 million gain on sale of a priority review voucher in 2024. Non-GAAP figures exclude acquisition amortization, impairments, restructuring, and equity investment gains or losses. Management uses non-GAAP EPS for incentive compensation and its 2025 guidance, so investors typically anchor on that measure, while also reviewing GAAP results for one-time items.
Why is 2025 guidance lower than 2024 results?
The 2025 non-GAAP EPS range of $15.25 to $16.25 is below 2024's $16.47, mainly because total revenue is expected to decline by a mid-single-digit percentage at constant currency. Multiple sclerosis product sales, which are the company's largest franchise, are expected to keep falling, and launch growth from LEQEMBI, SKYCLARYS, and ZURZUVAE is only expected to partially offset that decline. Guidance also includes about a $0.35 foreign exchange headwind. Management expects operating margin to be roughly flat, so lower revenue is the main driver of the EPS decline.
How is Biogen's cost base changing, and how much of the savings are already in the numbers?
The Fit for Growth program is expected to deliver about $1 billion in gross savings and $800 million net of reinvestment by the end of 2025. About $400 million of net savings have been achieved since the program started in 2023, and management expects to realize the remainder by year-end 2025. Non-GAAP R&D fell 15% and non-GAAP SG&A fell 3% in 2024. Combined R&D and SG&A for 2025 is guided to about $3.9 billion, so further savings will need to be realized to hold that level.
How significant is LEQEMBI's commercial progress and what are the next catalysts?
LEQEMBI generated approximately $87 million in global in-market sales in Q4 2024, including about $50 million in the U.S., and management described this as continued sequential growth. Biogen's reported Alzheimer's collaboration revenue was $60 million for the full year, reflecting its 50% share of net revenue and royalties. The FDA approved intravenous maintenance dosing, and the subcutaneous maintenance dosing BLA has a PDUFA date of August 31, 2025. Management believes the long-term opportunity remains significant, but the drug is still early in its launch.
How strong is Biogen's balance sheet and cash flow position?
Biogen generated $2.9 billion of operating cash flow and $2.7 billion of free cash flow in 2024. Year-end cash was about $2.4 billion against total debt of about $6.3 billion, for net debt of about $3.9 billion. Current portion of debt rose to $1.75 billion, which investors should monitor for refinancing needs. Diluted share count was steady at about 146 million, and the company did not disclose share repurchases in this filing. Guidance does not include future acquisitions or business development, so any large deal could change the capital allocation picture.

04—Continue

← View all 8-K filings